BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T044530
CREATED:20241024T112821Z
LAST-MODIFIED:20241024T112821Z
UID:39941-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:8th Antigen-Specific Immune Tolerance Drug Development Summit
DESCRIPTION:Advancing Curative Therapies for Autoimmune Diseases  \nBuilding on the success of last year’s meeting\, the 8th Antigen-Specific Immune Tolerance Summit will bring together 120+ end-to-end experts in immune tolerance for autoimmune diseases. \nAgenda highlights include: \n\nStandardizing the definition and biomarkers of tolerance to inform clinical endpoints for specific disease studies and work towards measurable milestones of efficacy\nDelving into antigen selection for complex autoimmune diseases with multiple antigen drivers to expand the wheelhouse of diseases immune tolerizing strategies can target including celiac disease\, Type 1 diabetes\, multiple sclerosis\, rheumatoid arthritis\, IBD\, and more\nAdvancing durable and efficacious ASIT therapeutics through early-stage clinical trials and beyond\n\nJoin your colleagues and thought leaders in February to take actionable insights back to your team at the industry’s only\, dedicated\, antigen-specific immune tolerance meeting. Join Eli Lilly\, AbbVie\, Pfizer\, Diamyd\, Moderna\, Toleranzia\, GRO Bio and more. \nFind out more here: https://ter.li/ujeia4
URL:http://www.pharmajournalist.com/event/8th-antigen-specific-immune-tolerance-drug-development-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250219
DTEND;VALUE=DATE:20250222
DTSTAMP:20260515T044530
CREATED:20241122T121650Z
LAST-MODIFIED:20241122T121650Z
UID:40111-1739923200-1740182399@www.pharmajournalist.com
SUMMARY:3rd Viral Vector Process Development & Manufacturing Summit
DESCRIPTION:In recent industry news\, AAV gene therapies are gaining momentum\, with groundbreaking achievements like RegenxBio’s RGX-121 trial for Hunter syndrome\, demonstrating significant improvements in neurodevelopmental skills. The global AAV therapy market\, valued at $1.5 billion in 2023\, is projected to skyrocket to $22.3 billion by 2029. However\, scaling up production remains a significant challenge\, highlighting the urgency for innovative solutions in viral vector manufacturing.​ \nThe 3rd Viral Vector Process Development & Manufacturing Summit returns to Boston to tackle these challenges head-on. Featuring over 16 expert speakers\, including Yuanli Song\, Associate Director at Sanofi\, the event offers cutting-edge insights into process optimization for viral vector production. Yuanli Song emphasized the importance of this summit\, saying\, “This summit is a vital platform that brings together experts from diverse fields to address and solve pressing challenges in viral vector process development and manufacturing. The 2025 meeting will witness valuable discussions that will help drive innovation and advance solutions for optimizing viral vector production.” \nThe agenda includes two interactive workshops and over 20 hours of insightful content designed to address upstream and downstream challenges\, improve yield\, and enhance scalability. Additionally\, attendees will benefit from 6+ hours of dedicated networking breaks\, fostering collaborations crucial for advancing this field. \nKey topics covered include: \n\nEnhancing capsid ratios and vector optimization\nInnovations in purification techniques\nSeamless tech transfer for scalability\nTackling high-dose production complexities\n\nThis summit is the ultimate opportunity for professionals from companies like Sanofi\, Kite\, Ultragenyx\, and others to stay at the forefront of viral vector manufacturing innovations. With 800+ gene therapy candidates in trials and the FDA’s evolving frameworks\, this event is essential for driving the next wave of scalable\, high–quality therapies​. \nView our agenda to find out more!
URL:http://www.pharmajournalist.com/event/3rd-viral-vector-process-development-manufacturing-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250218
DTEND;VALUE=DATE:20250220
DTSTAMP:20260515T044530
CREATED:20241127T124753Z
LAST-MODIFIED:20241127T124753Z
UID:40158-1739836800-1740009599@www.pharmajournalist.com
SUMMARY:Neuroscience Innovation Pharma Partnering Summit
DESCRIPTION:Significant breakthroughs in CNS biology\, coupled with innovative neuroscience technologies and a more supportive regulatory landscape\, have fueled increased investment and pharmaceutical interest in the CNS. \nWith AbbVie\, BMS\, and Lundbeck making major acquisitions in the last 12 months alone\, this wave of deal-making is redemption for biotech who kept the lights on and are building with greater strength than before. \nJoin the Neuroscience Innovation Pharma Partnering Summit to: \n\nConnect with a targeted critical mass of decision-makers aligned with your strategic and scientific goals.\nBuild stronger relationships with key pharma and investor contacts to emphasize your company’s competitive edge\nPosition your company at the front of scientific innovation to show where you add value\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/neuroscience-innovation-pharma-partnering-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250211
DTEND;VALUE=DATE:20250213
DTSTAMP:20260515T044530
CREATED:20250116T115239Z
LAST-MODIFIED:20250117T133524Z
UID:40306-1739232000-1739404799@www.pharmajournalist.com
SUMMARY:3rd Kinase Targeted Drug Discovery Summit
DESCRIPTION:The kinase drug discovery field is at a pivotal moment\, with recent breakthroughs from industry leaders such as Biogen\, A-Alpha Bio\, and Proxygen paving the way for exciting new approaches in targeting kinases\, particularly in targeted protein degradation. \nWith ongoing challenges including selectivity and resistance in small molecule inhibitors\, these hurdles limit the therapeutic applications and call for in-depth discussions focused on innovative future strategies for kinase targeted drugs. \nJoin 60+ peers at the 3rd Kinase Targeted Drug Discovery Summit; the premier\, target-specific conference designed to provide you with ground-breaking insights to revolutionize your kinase biology. \n\nDiscover cutting-edge developments in small molecule therapeutics\, including PROTACs\, molecular glues\, and allosteric inhibitors\nEnhance drug selectivity & tackle resistance head-on\, and identify optimal combination partners\nLead the charge in creating first-class kinase-targeted drugs that can ultimately combat disease indications and transform patient outcomes!\n\nAttendance is complimentary for drug developers & researchers (subject to T&Cs) – we’d love to welcome you to Boston in February!
URL:http://www.pharmajournalist.com/event/3rd-kinase-targeted-drug-discovery-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250129
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T044530
CREATED:20241031T113348Z
LAST-MODIFIED:20241031T113527Z
UID:40005-1738108800-1738281599@www.pharmajournalist.com
SUMMARY:9th Tumor Models San Francisco Summit 2025
DESCRIPTION:Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling better and more accessible characterization of therapeutic pathways than ever before. The challenges and opportunities in preclinical and translational research are constantly evolving\, and it has never been more critical to benchmark and share cross-industry learnings and case studies to de-risk the move to the clinic. \nReuniting 180+ Preclinical\, Translational\, Discovery\, Pharmacology\, and Biology experts to share case studies in improving target selection\, facilitating biomarker discovery\, and achieving clinical translatability\, the 9th Tumor Models San Francisco Summit is the definitive industry forum uniting the West Coast ecosystem of pharma and biotech to collaboratively advance the frontier of oncology research to the clinic.Dates: December 10-12\, 2024. \n5 Must-Attend Case Studies in 2025:\n\n\nInterrogate the translational relevance of humanized mouse models and investigate data indicating translational relevance to optimize selection criteria with Amgen\nNavigate ADC activity in immunocompetent models across syngenic and humanized models to assess clinical relevance and optimize dosing with AstraZeneca\nEvaluate T cell engagers with additional functionality and selection rationale for humanized mouse models including PBMCs\, transgenic and tox models with Zymeworks\nOptimize decision making in outsourcing or developing internal capabilities for translational studies through cost-benefit models across multiple modalities with AstraZeneca\nExplore combination dosing strategies in bispecifics and CAR-T therapies and evaluate toxicity in mouse models to optimize targeted cytokine therapies with Regeneron
URL:http://www.pharmajournalist.com/event/9th-tumor-models-san-francisco-summit-2025/
LOCATION:Grand Hyatt San Francisco\, 345 Stockton St\, San Francisco\, CA\, 94108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250128
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T044530
CREATED:20241127T123357Z
LAST-MODIFIED:20241127T123357Z
UID:40145-1738022400-1738281599@www.pharmajournalist.com
SUMMARY:3rd Ophthalmic Drug Delivery Summit
DESCRIPTION:Fresh from the reapproval of Roche/Genentech’s Susvimo\, positive readouts for sustained release implants\, and suprachoroidal delivery revolutionizing gene therapy delivery to the retina\, matching the right delivery route to the right drug has become an unavoidable topic for ophthalmology biopharma. \nThe 3rd Ophthalmic Drug Delivery Summit is the premier gathering for the industry to discuss and explore innovations and future directions for ophthalmic device and formulation development. Delve into the latest in-depth analysis of intravitreal\, subretinal\, suprachoroidal and topical delivery and explore advancements in ophthalmic pharmacology. \nWith an ever-growing market opportunity\, the industry is in an arms race to demonstrate the clinical benefits of longer lasting efficacy and less invasive drug delivery through alternative administration routes and novel ocular devices. Reuniting 60+ ophthalmic delivery innovators in sunny San Francisco\, the 3rd Ophthalmic Drug Delivery Summit is the only industry-focused meeting dedicated to translating more efficacious\, longer lasting\, and less invasive retinal delivery. Across 3 jam-packed days\, join clinical and preclinical ocular experts\, ophthalmic device engineers\, product development leaders and formulation specialists to delve a range of ocular drug-delivery systems striving to maintain drug concentrations\, reduce dosage frequency\, and overcome ocular barriers. \nThis meeting is your one-stop-shop to gather key updates on cutting-edge technologies\, ophthalmic pharmacology and to compare routes of administration capabilities to overcome anatomical barriers\, enhance bioavailability\, and improve patient outcomes such as: \n\nOptimizing sustained release formulations and release kinetics to fine-tune dosing for long-lasting retinal delivery with Genentech\, Ocular and Alcon\nEvaluating the durability and safety of delivering drugs to the retina via suprachoroidal delivery with Everads\, Genentech and Clearside\nUtilizing gene therapy transduction via sub retinal and para retinal delivery to the retina with REGENXBIO\, GelMEDIX and Ray Therapeutics\nTroubleshooting species differences and biocompatibility with ocular models to accelerate delivery translation with Genentech and Wake Forest University\nOvercoming clinical trial hurdles and achieving operational synergies to streamline development with Aviceda\, AbbVie and Regeneron\n\nDon’t miss this exclusive opportunity to meet world class ophthalmic delivery experts from the likes of Genentech\, AbbVie\, Bayer\, Clearside Biomedical\, Ocular Therapeutix\, REGENXBIO\, Regeneron\, Eyepoint Pharmaceuticals\, and more.
URL:http://www.pharmajournalist.com/event/3rd-ophthalmic-drug-delivery-summit/
LOCATION:The Clift Royal Sonesta San Francisco\, 495 Geary St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250128
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T044530
CREATED:20241031T112719Z
LAST-MODIFIED:20241031T112719Z
UID:39999-1738022400-1738281599@www.pharmajournalist.com
SUMMARY:3rd Molecular Glue Drug Development Summit
DESCRIPTION:The 3rd Molecular Glue Drug Development Summit is returning to bring together leaders across biopharma covering the depth and breadth of the molecular glue field from rational discovery to improving toxicity\, PKPD\, and late-stage development. Don’t miss out on the unparallel learning and networking opportunities on offer at this summit and join 90+ pioneering Directors\, Vice Presidents\, and Heads of Medicinal Chemistry\, Structural Biology\, and Drug Discovery to kickstart your 2025 R&D and fast-track your glues to patients in need faster. \nTo know more visit: https://ter.li/rwb5uq
URL:http://www.pharmajournalist.com/event/3rd-molecular-glue-drug-development-summit/
LOCATION:The Royal Sonesta Boston\, 40 Edwin H Land Blvd\, Cambridge\, MA\, 02142\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250128
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T044530
CREATED:20241008T142442Z
LAST-MODIFIED:20241008T144847Z
UID:39886-1738022400-1738281599@www.pharmajournalist.com
SUMMARY:6th RNAi-Based Therapeutics Summit
DESCRIPTION:RNAi Therapeutics holds more promise than ever in treating many diseases beyond the liver\, with momentum in this field growing stronger than ever. Breakthrough companies such as Argonaute RNA and Kate Therapeutics have secured funding to propel their innovative RNAi candidates and delivery platforms\, as well as pharma giants partnering with innovative biotech companies to advance RNAi candidates into the clinic. \n \nThe 6th RNAi-Based Therapeutics Summit is returning to Boston to showcase the latest delivery technologies\, data from clinically successful extra-hepatic targeting\, cutting-edge AI tools to assist payload design\, and breakthrough chemical modifications that enhance stability\, allowing for precise therapeutic delivery. \nUniting 70+ leaders of the RNAi world\, this Summit will empower experts to pioneer their RNAi candidates into clinically successful therapies. Bringing together technical and strategic experts from Novo Nordisk\, Alynlam\, Switch Therapeutics\, Aro Biotherapeutics\, Novartis\, Comanche Biopharma\, and more\, this meeting is a unique gathering of RNAi’s sharpest minds\, dedicated to progressing the next wave of RNAi therapeutics to improve healthcare for patients in need. \nWant to learn more? Download our official brochure here: https://ter.li/00r79n
URL:http://www.pharmajournalist.com/event/6th-rnai-based-therapeutics-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250128
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T044530
CREATED:20241008T141023Z
LAST-MODIFIED:20241008T141023Z
UID:39875-1738022400-1738281599@www.pharmajournalist.com
SUMMARY:4th mRNA-Based Therapeutics Summit Europe
DESCRIPTION:The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt\, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets\, never-before-seen pre-clinical and clinical data\, and demonstrating key routes to commercial success for mRNA therapy and vaccine R&D pipelines. \nWhether you’re entering the mRNA arena for the first time or a well-seasoned mRNA veteran\, with two dedicated tracks of content spanning discovery through commercialisation\, this forum will equip you with the know-how and connections to make rapid advances in your work with partnering and collaborative networking opportunities spread throughout. \nAssembling 200+ mRNA enthusiasts from across Europe\, Asia and the globe\, this is your one-stop-shop to gain unparalleled overview of cutting-edge R&D innovations\, whilst diving deep into end-to-end development strategy to revolutionise the next wave of mRNA medicines towards clinical reality. \nDownload the event guide for full details: https://ter.li/qd1z5z
URL:http://www.pharmajournalist.com/event/4th-mrna-based-therapeutics-summit-europe/
LOCATION:Sheraton Frankfurt Airport Hotel & Conference Center\, Hugo-Eckener-Ring 15/Terminal 1\, Frankfurt am Main\, 60549\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250127
DTEND;VALUE=DATE:20250130
DTSTAMP:20260515T044530
CREATED:20241114T140137Z
LAST-MODIFIED:20241114T140346Z
UID:40094-1737936000-1738195199@www.pharmajournalist.com
SUMMARY:The 3rd Medical Device Software Development Summit Europe
DESCRIPTION:Integrating Expertise from Software Development\, Quality Assurance\, Regulatory Affairs\, & Product Teams to Drive Innovation in Alignment with Global Regulatory Guidelines\, AI & ML Enabled Software\, Cybersecurity\, & Agile Methodologies: \nThe European market is capturing 30% of the global medical device field driven by rapid advances in innovative software\, AI\, and ML. But as medical device developers are met with tedious submission processes\, ever-changing software patches\, and red tape at every turn\, it has never been more important to break out of cross-functional silos and stay two steps ahead of compliance guidelines. \nDedicated to unravelling a matrix of multi-layered European and global regulations\, mitigating vulnerabilities in security\, and managing updates to legacy devices\, the 3rd Medical Device Software Development Summit Europe is uniting medical device giants and innovative start-ups to share case studies and best practices in advancing and maintaining compliance of innovative software. \nReturning to Munich in January\, this Summit will be shining the spotlight on: \n\nWorking strategies shown through examples of documentation for AI enabled medical device software\nImplementing automation tools to establish feedback loops throughout the software development process\nImplementing rigorous data validation and cleansing processes to ensure reliability of training datasets for AI models\nCreating synergy between business and engineering through a unified data strategy\n\nUniquely positioned to share strategic guidance in optimising efficiency in regulatory submissions\, streamlining development processes\, and embedding compliant AI and ML in medical devices\, join 70+ CTOs\, Heads of Software\, Product\, RA\, and QA to harmonise cross-functional objectives\, accelerate time to market\, and optimise updates to legacy devices. \nCurious to find out more? Download the Agenda here: https://ter.li/5y1i73
URL:http://www.pharmajournalist.com/event/the-3rd-medical-device-software-development-summit-europe/
LOCATION:H4 Hotel Munchen Messe\, Konrad-Zuse-Platz 14\, Munchen\, 81829\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241211
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044530
CREATED:20241108T100238Z
LAST-MODIFIED:20241108T100238Z
UID:40052-1733875200-1734047999@www.pharmajournalist.com
SUMMARY:3rd PAT & Real Time Quality Summit
DESCRIPTION:Join 100+ leading PAT scientists\, engineers\, process development\, CMC\, MSAT and quality experts at the 3rd Annual PAT & Real Time Quality Summit. Explore cutting-edge data-driven case studies\, engage in dynamic roundtables and deep dive into KOL-led panel debates. This summit is your gateway to staying ahead of the innovation curve\, exceeding stakeholder expectations for faster time to market\, and unlocking significant ROI through transformative PAT and real-time quality control. \nWith drug developers and manufacturers facing closer scrutiny on product quality than ever before\, it’s time to make the most of evolving process analytical technology (PAT) to design robust and cost-effective control strategies to understand more about your biopharmaceutical products. \nRecent blockbusters like GLP-1 peptides have sparked unprecedented investment into advanced manufacturing strategies\, such as Novo Nordisk’s recent $11B acquisition to expand manufacturing capacity. The maturity of PAT tools and the development of sophisticated software and chemometrics now provide the perfect opportunity to revolutionize traditional quality and analytical approaches\, achieving the digital manufacturing maturity necessary for the future. \nDon’t miss your chance to connect ground-breaking technologies with real-world manufacturing investment decisions. This is the only PAT conference designed exclusively for the pharmaceutical and biopharmaceutical community\, where insights turn into action. \nTo know more visit: https://ter.li/e3xja8
URL:http://www.pharmajournalist.com/event/3rd-pat-real-time-quality-summit/
LOCATION:Philadelphia Airport Marriott\, Terminal B\, One Arrivals Road Terminal B\, Arrivals Rd\, Philadelphia\, PA\, 19153\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044530
CREATED:20241114T161818Z
LAST-MODIFIED:20241114T161908Z
UID:40104-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:The 4th Applied Biocatalysis & Enzyme Engineering Summit
DESCRIPTION:Join industry leaders like Eli Lilly\, Merck\, Novo Nordisk and Pfizer at the 4th Applied Biocatalysis & Enzyme Engineering Summit (December 10-12\, 2024 – Philadelphia\, PA). This is your perfect moment to network with enzyme discovery\, engineering\, biocatalysis\, and process chemistry professionals from both industry and academia. \nCapitalize on Enzyme Evolution through HTP Screening\, Advanced Engineering & Deploy Maturing Biocatalysis Techniques in Small Molecules & Complex Modalities. \nNow with a sharper focus on enzyme engineering and expanded coverage of biocatalysis-derived oligonucleotides\, peptides and other large biologics. Plus\, dive into brand-new biopharma case studies designed to boost enzyme efficiency and therapeutic yields. \nWhy Attend? \n– Revolutionize Biologics Development: Discover cutting-edge oligonucleotide production case studies that are setting new standards in biologics \n– Streamline Enzyme Discovery: Learn how to prioritize and engineer enzymes from early-stage proof of concept to accelerate your pipeline \n– Fast-Track Decision Making: Master modern prediction methods and sophisticated high-throughput techniques to refine enzyme selection \n– Optimize Small Molecule Biocatalysis: Gain insights from pharma-led projects focused on enhancing activity\, yields and green chemistry \nWhat to Expect? \n– Exclusive interactive discussions exploring ML-informed enzyme design techniques \n– Poster session opportunity to showcase your current work and gain feedback from 60+ senior peers \n– 20+ industry speakers to inspire you and help you take advantage of biocatalysis in its prime \n– Pharma and academia-led workshops to perfect enzyme decision-making and late process optimization \nLet’s innovate and elevate drug development pipelines together through the power of green biocatalysis. \nTo know more visit: https://ter.li/t9gd14
URL:http://www.pharmajournalist.com/event/the-4th-applied-biocatalysis-enzyme-engineering-summit/
LOCATION:Wyndham Philadelphia Historic District\, 400 Arch Street\, Philadelphia\, PA\, 19106\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044530
CREATED:20240930T131805Z
LAST-MODIFIED:20240930T131943Z
UID:39832-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:4th ADC Target Selection Summit
DESCRIPTION:The 4th ADC Target Selection Summit returns to outline approaches to identify and validate novel targets that can be clinically and commercially successful and discuss rationale behind selecting a target to support with the development of future first-in-class ADCs. \nWith sessions led by Almac Discovery\, AstraZeneca\, Bolt Biotherapeutics\, and many other industry leaders\, leave this meeting equipped to perform a strategic evaluation of when and how to approach developing an ADC against a novel target. Enhance this knowledge with exclusive insight from brand-new biotechs\, Epifold and GO Therapeutics striving to leave their mark on the ADC field by sharing their innovative strategy which has reaped success in novel ADC targeting. \nDon’t miss this opportunity to join an audience of 80+ highly focused biologists\, discovery researchers\, computational biologists and bioinformaticians\, as well as senior C-level and Alliance Management experts. End your 2024 ADC conference calendar with the perfect balance of scientific and strategic level conversations and gain the know-how to invigorate your target selection strategy and propel more ADCs to first-in-class therapeutics. \nView all the industry strategies\, innovation sessions and networking opportunities in the FREE event guide here: https://ter.li/un31n9
URL:http://www.pharmajournalist.com/event/4th-adc-target-selection-summit/
LOCATION:DoubleTree by Hilton Hotel\, San Diego Downtown\, 1646 Front Street\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044530
CREATED:20240904T120903Z
LAST-MODIFIED:20240904T120903Z
UID:39686-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:8th Complement-Based Drug Development Summit
DESCRIPTION:With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement for PNH\, which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies? \nWith assets in nephrology\, ophthalmology\, neurodegeneration\, and inflammation all progressing through to the clinic\, the immunology landscape is preparing to be shaken up with companies making huge strides to achieve and improve the efficacy of complement-targeted therapies. \nJoin 100+ industry leaders\, scientists\, and clinicians at the premier\, end-to-end\, 8th Complement-Based Drug Development Summit to shape the future of complementtargeted therapies. Across 3 days of content\, you can expect discussions spanning: \n\nStrategic targeting and preclinical breakthroughs for the next-generation of complement inhibitors and comprehensive insights into the complexities of the complement pathways and selection of inhibition targets\nNavigating complement clinical trials and exploring indication expansion strategy for complement inhibitors beyond their initial disease indication\nExploring the potential for combination therapies to overcome compensatory mechanisms and ensure patient comfort\nMoving from targeting rare disease with complement inhibitors to larger patient populations\nNavigating efficacy and safety of complement inhibitors to bring safer and more tolerable therapies to patients faster\n\nKey benefits of attending: \n\nDelve into the pathophysiology of different complement pathways for the specific targeting of acute and chronic inflammatory diseases with Apterion Therapeutics\, Annexon Bio\,and Sanofi to determine the most effective pathway when developing complement inhibitors\nExplore the potential for combination therapies with existing complement therapies and other modalities with CSL Behring for a more precise approach to hit inflammation and autoimmune diseases harder beyond complete immunosuppressive approaches.\nDiscuss the move from targeting rare diseases with complement inhibitors to more common diseases with IgM Biosciences\, Grid Therapeutics\,and Astellas\, to target larger patient populations\nEvaluate the value proposition of targeting complement proteins with advanced therapeutics such as RNAi and gene therapies to determine the optimal mode of action and make complement inhibitors more targeted with Beacon Therapeutics and Arrowhead Pharmaceuticals\n8 Brand New Data readouts focusing on the translational and clinical stages of complement inhibitor development to help you stay up to date as this field makes strides towards regulatory approval
URL:http://www.pharmajournalist.com/event/8th-complement-based-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044530
CREATED:20240828T110543Z
LAST-MODIFIED:20240828T110543Z
UID:39644-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:7th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus\, there have been many valuable collaborations entering the RNA-targeting field\, accelerating efficacious and selective small molecules targeting RNA directly\, RNA-binding proteins\, and RNA/protein complexes. \nHence\, as the go-to meeting for the RNA-targeting small molecule community\, the 7th Annual RNA-Targeted Drug Discovery & Development Summit returns to Boston this December. Increase your knowledge of RNA tertiary structures\, delve into innovative preclinical modeling strategies\, and identify optimal chemical features for advancing specific\, efficacious\, and safe small molecules. \nCurated in collaboration with large pharma\, innovative biotech\, and leading academics\, the 7th RNA-Targeted Drug Discovery & Development Summit returns with 3 jam-packed days and unrivaled networking opportunities with the key stakeholders to accelerate the discovery of disease-relevant RNA\, optimize small molecule design\, and uncover novel targets on proteins\, enzymes\, and RNA/protein complexes to increase the landscape of treatable diseases. \nUnite with 100+ RNA Science\, Medicinal Chemistry\, Structural Biology & Biophysics experts from the likes of AstraZeneca\, Sanofi\, Novartis\, PTC Therapeutics\, ReviR Therapeutics\, Rgenta Therapeutics\, Accent Therapeutics\, and more at the most comprehensive and definitive event for the community\, the 7th RNA-Targeted Drug Discovery & Development Summit\, to accomplish faster and smoother translation of RNA-targeted therapies towards the clinic. \nTo know more visit: www.rna-drugdiscovery.com
URL:http://www.pharmajournalist.com/event/7th-rna-targeted-drug-discovery-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044530
CREATED:20240828T105923Z
LAST-MODIFIED:20240828T105923Z
UID:39639-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:4th Rare & Genetic Kidney Disease Drug Development Summit
DESCRIPTION:With recent accelerated approval wins\, positive clinical trial readouts\, progression through clinical pipelines and exciting mergers and acquisitions\, it has certainly been an industry-defining year for the rare and genetic renal space. \nIn the context of rapid progress and a mounting desire to propel game-changing novel therapies that will add to the arsenal of therapeutic options for patients\, the 4th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston. This unique event for the industry\, academic KOL\, and patient advocacy nephrology community provides an unrivalled opportunity to discuss acceleration of clinical advancements in orphan kidney disease populations. \nJoin Mironid\, AstraZeneca\, Novartis\, Maza Therapeutics\, Harvard Medical School\, and more as you dive into critical topics investigating IgAN\, FSGS\, PKD\, Alport Syndrome and more therapeutic areas to foster partnerships and accelerate game-changing therapies into the clinic and to rare renal diseases patients in need. \nView the full event program here: https://ter.li/ncjxqh
URL:http://www.pharmajournalist.com/event/4th-rare-genetic-kidney-disease-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044530
CREATED:20240719T112018Z
LAST-MODIFIED:20240722T133910Z
UID:39410-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:2nd Covalent Drug Discovery & Development Summit
DESCRIPTION:Discover & Develop Selective\, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology\, Immunology & Beyond \nThe covalency renaissance continues as biopharma race to unlock hard-to-target proteins across oncology\, immunology and CNS. Yet\, key challenges remain in balancing reactivity and sensitivity\, de-risking the ligandability of alternative residues\, and tackling PKPD disconnects and efficiency bottlenecks\, \nBringing together 100+ covalency experts\, the 2nd Covalent Drug Discovery & Development Summit returns as the only dedicated forum to comprehensively cover discovery to translation and clinical development of covalent therapeutics. \n\nDates: December 10-12\, 2024\nLocation: Hilton Boston Logan Airport\, Boston\, Massachusetts\nEvent Program: https://ter.li/bz5jjg\n\nDive into extensive technical content spanning target selectivity\, hit screening\, lead optimization and covalent warhead design\, network with over 100 heads\, directors and VPs of Proteomics\, Medicinal Chemistry\, Chemical Biology\, Discovery Biology and Pharmacology\, and hear from the brightest minds of academia as they share their latest findings. \nDownload the program here: https://ter.li/bz5jjg \nRegister your place here (and take advantage of group discounts of up to 20% when registering your team of two or more!): https://ter.li/8257lj
URL:http://www.pharmajournalist.com/event/2nd-covalent-drug-discovery-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T044530
CREATED:20240919T065329Z
LAST-MODIFIED:20240920T112649Z
UID:39788-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:5th Genome Editing Therapeutics Summit
DESCRIPTION:Just 11 years after Emmanuelle Charpentier and Jennifer Doudna’s seminal CRISPR discovery\, Casgevy marks the first approved gene-editing therapy\, a major milestone for the field. This breakthrough signals the beginning of a revolution in treating genetic diseases\, with a rapidly growing pipeline of precision genome-editing techniques emerging. \n \nThe 5th Genome Editing Therapeutics Summit (formerly the CRISPR 2.0 Sumit) is the leading industry event dedicated to advancing gene-editing technologies in therapy. Attendees can expect data-rich presentations\, expert panels\, and interactive sessions covering both established and emerging technologies. The summit will explore key topics such as novel nucleases\, base and prime editing\, multiplex editing\, and precision tools enabling small and large genome modifications. Additionally\, it will highlight epigenome editing\, recombinase and transposon-based technologies\, and innovative delivery vehicles. \nOver three days\, industry and academic leaders will present the latest research on cutting-edge therapies\, discussing the safety\, precision\, and regulatory compliance necessary for successful development. This summit is the only event prioritizing drug development first\, with a strong focus on creating robust safety profiles\, detecting off-target effects\, and facilitating investigational new drug (IND) filings. \nParticipants will gain actionable insights to improve the precision and safety of their technologies\, enhancing their ability to perform targeted edits and streamline the path to the clinic for lead programs. \nJoin us and be part of the gene-editing revolution shaping the future of therapeutic development!
URL:http://www.pharmajournalist.com/event/5th-genome-editing-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T044530
CREATED:20240809T123626Z
LAST-MODIFIED:20240813T083728Z
UID:39561-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:Personalized Vaccine Summit
DESCRIPTION:The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) returns to Boston bringing together the top industry players developing individualized approaches across several modalities including mRNA\, DNA\, peptides\, viral\, dendritic cell and more to share how they are conquering common challenges\, developing novel bioinformatic strategies\, and achieving clinical efficacy. \nThis is the only conference uniting biopharma companies working on different vaccine modalities to develop an immune-responsive personalized cancer vaccine for one goal – cure cancer! Join the likes of BioNTech\, CureVac\, Imvax\, NousCom\, with our expert speaker faculty of leaders and industry pioneers\, for 3 days of content and 15+ deep dive case studies. \nInterested? Find out more here. https://ter.li/lg5a1h
URL:http://www.pharmajournalist.com/event/personalized-vaccine-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T044530
CREATED:20240808T111110Z
LAST-MODIFIED:20240808T111110Z
UID:39549-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:6th Cell Therapy Analytical Development Summit
DESCRIPTION:As the field of cell therapy evolves\, integrating the latest technologies and robust analytical methods has never been more crucial. Join us at the 6th Cell Therapy Analytical Development Summit to discover how to enhance your analytical strategies and accelerate product development through IND and clinical trials\, leading to more efficient regulatory approval. \nWhy Attend? \n\nExplore the latest advancements in immunophenotype\, cell-based\, and molecular assays.\nConnect with over 40 industry leaders and experts from companies like Bristol Myers Squibb\, Takeda\, and Kite Pharma to delve into assay matrices\, phase-appropriate development\, and specifications.\nParticipate in discussions on overcoming challenges in product characterization\, assay development\, and scale-up\, sharing innovative technologies and best practices to advance cell therapies.\n\nJoin us to elevate the development of safe and effective autologous and allogeneic cell therapies to new heights! \nDownload the NEW 2024 program
URL:http://www.pharmajournalist.com/event/6th-cell-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241202
DTEND;VALUE=DATE:20241205
DTSTAMP:20260515T044530
CREATED:20240808T110905Z
LAST-MODIFIED:20240808T110905Z
UID:39544-1733097600-1733356799@www.pharmajournalist.com
SUMMARY:2nd Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:The 2nd Cell Therapy for Autoimmune Disease Summit returns to Philadelphia bigger and better after last year’s explosive debut as the only meeting covering every aspect of bringing cell therapies to the autoimmune space. \nThis year’s agenda brings you the opportunity to learn the A-Zs of accelerating your candidates to be the first in the market and finally bring the cure for an autoimmune indication. Leading experts including Cartesian Therapeutics\, Bristol Myers Squibb\, the University of Pennsylvania\, ImmPACT Bio and more\, will cover their latest clinical updates\, next-generation candidates\, novel antigen targets\, and translational biomarkers to turbocharge the development of cell therapies for autoimmune disease. \nThis is your chance to connect with top cell therapy pioneers\, clinicians\, investors\, and wavemakers who share a focus on accelerating this approach for autoimmune patients to realize a curative treatment. \nFind out more here.
URL:http://www.pharmajournalist.com/event/2nd-cell-therapy-for-autoimmune-disease-summit/
LOCATION:Sheraton Philadelphia Downtown\, 201 N 17th Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241126
DTEND;VALUE=DATE:20241129
DTSTAMP:20260515T044530
CREATED:20240906T130002Z
LAST-MODIFIED:20240906T130002Z
UID:39730-1732579200-1732838399@www.pharmajournalist.com
SUMMARY:GPCRs-Targeted Drug Discovery Summit Europe
DESCRIPTION:As structural biology tools and screening technologies advance\, the GPCR super family continues to be a hot area of drug discovery\, with the potential to treat a plethora of diseases. For the first time ever\, the GPCRs-Targeted Drug Discovery Summit Europe is coming to London\, with the aim of overcoming pharmacology challenges and advancing the next wave of GPCR drug discovery. \nThis November\, leading European biopharma experts and trail-blazing opinion leaders of academia are uniting under one roof at this inaugural Meeting to share data\, discuss the latest advances in drug discovery. This Summit will deconvolute signalling bias\, reveal novel targets for successful therapeutic interventions and fast-track structurally guided GPCR drug discovery across inflammatory\, cardiovascular and metabolic indications and beyond. \nBringing together technical experts from Eli Lilly\, AstraZenenca\, Roche\, ThirtyFiveBio\, OMass Therapeutics and more\, this Meeting aims to unlock previously undruggable targets\, reveal the significance of genetic variants of GPCRs\, showcase ground-breaking drug discovery tools and streamline the translation of small molecules and biologics into clinically successful therapies. \nJoin 70+ Senior Scientists\, Heads and Directors of Drug Discovery\, Biology\, Chemistry and Pharmacology for 3 days of technical and data driven case studies and discussions\, enabling you and your team to accelerate novel GPCR-targeted drug discovery. \nTo know more visit: https://ter.li/os0qc7
URL:http://www.pharmajournalist.com/event/gpcrs-targeted-drug-discovery-summit-europe/
LOCATION:Millennium Hotel and Conference Centre Gloucester\, 4-18 Harrington Gardens\, South Kensington\, London\, SW7 4LH\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241121
DTEND;VALUE=DATE:20241123
DTSTAMP:20260515T044530
CREATED:20240904T114349Z
LAST-MODIFIED:20240904T121218Z
UID:39681-1732147200-1732319999@www.pharmajournalist.com
SUMMARY:3rd Liquid Biopsy Surveillance Summit
DESCRIPTION:Liquid biopsies are revolutionizing clinical trials\, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance. This breakthrough enables precise patient stratification\, ensuring they receive the most effective and safe treatments. The 3rd Liquid Biopsy Surveillance Summit returns as the leading East Coast forum solely dedicated to MRD detection in clinical trials to improve stage response monitoring to get patients earlier access to precision treatments. \n \nExpect to hear critical insights from leading biopharma\, oncologists and diagnostic providers to utilise liquid biopsies as surrogate endpoints in clinical trials\, guide dosing decisions and enable the development of precise drugs for patients with unmet needs in oncology and beyond. \nJoin your peers from Biomarker\, Translational and Clinical Development teams to more accurately monitor drug response through MRD assessments for improved treatment regimens from early to late stage clinical trials to improve patient outcomes. \nThis event is free to attend* if you work for a drug developer\, researcher\, or academic institution. \nDownload the event guide for full details: https://ter.li/ig2qtr \n*View the website for full T&Cs: https://ter.li/h7ri3w
URL:http://www.pharmajournalist.com/event/3rd-liquid-biopsy-surveillance-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241120
DTEND;VALUE=DATE:20241122
DTSTAMP:20260515T044530
CREATED:20240920T113804Z
LAST-MODIFIED:20240924T114350Z
UID:39796-1732060800-1732233599@www.pharmajournalist.com
SUMMARY:Portfolio Strategy & Decision Making for Biopharma Summit
DESCRIPTION:Join us at the inaugural Portfolio Strategy & Decision Making for Biopharma Summit – the must-attend event for pharma and biotech leaders seeking to sharpen their portfolio strategies in today’s dynamic market. \nGain exclusive insights into leveraging advanced data analytics\, forecasting tools\, and innovative approaches to enhance decision-making. This summit will showcase real-world case studies and best practices from both established big pharma and agile biotech companies\, helping you navigate market volatility with confidence. \nNetwork with over 60 industry leaders and engage in discussions focused on boosting cross-functional collaboration and exploring partnership opportunities. Learn how to align stakeholders\, mitigate risks\, and drive sustainable growth through strategic portfolio management. \nIn an era of rapid change and unprecedented challenges in the biopharma market\, this event is essential for staying ahead. Don’t miss the opportunity to equip yourself with the tools and knowledge to adapt\, respond\, and implement strategies that ensure portfolio success. \nKey Themes Include: \n\nAdvanced data analytics for better decision-making\nRisk mitigation and portfolio optimization\nCross-functional collaboration and partnerships\n\nJoin us to analyze\, adapt\, and respond to today’s biopharma challenges—position yourself for success!
URL:http://www.pharmajournalist.com/event/portfolio-strategy-decision-making-for-biopharma-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241119
DTEND;VALUE=DATE:20241121
DTSTAMP:20260515T044530
CREATED:20240806T120430Z
LAST-MODIFIED:20240809T122433Z
UID:39503-1731974400-1732147199@www.pharmajournalist.com
SUMMARY:LEAP HR: Emerging Biopharma
DESCRIPTION:Mark your calendars for November because LEAP HR: Emerging Biopharma is back! Returning to Boston from November 19-20\, this event is designed specifically for CHROs\, CPOs\, and Heads of HR at the heart of Emerging Biopharma organizations. Over the course of two days\, we will unite the most senior leaders from Emerging Biopharma companies across the US for unmissable content and invaluable networking opportunities. \nIn today’s rapidly evolving biotech landscape\, there has never been a more crucial time for HR leaders to come together. With limited resources and funding\, the challenges are greater than ever. LEAP HR: Emerging Biopharma provides a platform to address these challenges head-on\, offering strategies to enhance HR efficiency and prepare for a future brimming with investment and growth opportunities. \nThis event is your best opportunity to delve deeply into the pressing issues that senior leaders face daily. Topics will include rethinking organizational efficiencies\, adapting to new agile working methodologies\, and genuinely engaging and retaining critical biopharma talent. Through a series of insightful sessions\, participants will explore how to build high-impact strategies that align closely with business needs and help navigate today’s volatile biotech market. \nUnveiling of 30+ case studies showcasing how HR leaders are overcoming industry challenges\, gain actionable insights into engaging and developing employees\, retaining essential talent\, and preparing for future adversities. By sharing these real-world examples\, you will leave equipped with the tools you need to foster resilience and innovation within their organizations. \nJoin us in Boston this November for LEAP HR: Emerging Biopharma and become part of a dynamic community of HR leaders dedicated to shaping the future of the biopharma industry. Don’t miss this chance to network with peers\, gain fresh perspectives\, and develop strategies that will help your organization thrive in an increasingly competitive market. Be prepared to return to your organization with renewed energy and practical solutions to drive success in the challenging yet promising world of Emerging Biopharma. \nFind out more now: https://ter.li/jqplmd
URL:http://www.pharmajournalist.com/event/leap-hr-emerging-biopharma/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241119
DTEND;VALUE=DATE:20241122
DTSTAMP:20260515T044530
CREATED:20240805T115824Z
LAST-MODIFIED:20240805T115824Z
UID:39492-1731974400-1732233599@www.pharmajournalist.com
SUMMARY:8th Antifibrotic Drug Development Summit
DESCRIPTION:The landmark FDA approval of the first MASH therapeutic\, the orphan drug designation for systemic sclerosis trials\, and the rapid advancement of IPF treatments through clinical phases have ignited a transformative era in fibrosis research. Now more than ever experts are doubling down on fibrosis. \nAs the focus on innovative therapies intensifies\, there is a pressing need for cutting-edge strategies that can overcome preclinical and clinical challenges has never been more critical. With that\, I’m delighted to announce the return of the 𝗔𝗻𝘁𝗶𝗳𝗶𝗯𝗿𝗼𝘁𝗶𝗰 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 for its 𝟴𝘁𝗵 𝘆𝗲𝗮𝗿 as the fibrosis community’s premier event\, uniting industry experts and key opinion leaders across Pulmonology\, Hepatology\, Rheumatology\, Nephrology\, Cardiology\, and Gastroenterology. \nGathering decision makers to share cross fibrosis insights on innovative strategies to navigate the shared fibrosis challenges from discovery to novel targets\, preclinical models\, biomarkers\, and early-stage clinical trials. Gain exclusive insights and strategies to apply to your own research accelerating the development of truly transformative\, disease-modifying\, ‘antifibrotic’ therapeutics. \nWhether focusing on 𝗜𝗣𝗙\, 𝗠𝗔𝗦𝗛\, 𝘀𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝘀𝗰𝗹𝗲𝗿𝗼𝘀𝗶𝘀\, 𝗸𝗶𝗱𝗻𝗲𝘆 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀\, 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀\, 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝗻𝗴 𝗜𝗕𝗗 or 𝗮𝗻𝗼𝘁𝗵𝗲𝗿\, this summit is your collective forum to propel innovative and efficacious antifibrotic therapeutics to patients in need. \nJoin us at the 8th AFDD Summit to be part of the conversation\, share your insights\, and discover the innovations that are transforming fibrosis treatment. \nTo know more visit: https://ter.li/01itbv
URL:http://www.pharmajournalist.com/event/8th-antifibrotic-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241118
DTEND;VALUE=DATE:20241121
DTSTAMP:20260515T044530
CREATED:20240808T110613Z
LAST-MODIFIED:20240808T110613Z
UID:39537-1731888000-1732147199@www.pharmajournalist.com
SUMMARY:2nd Donor Selection & Cell Source Summit
DESCRIPTION:Join us at the 2nd Donor Selection & Cell Source Summit – an unparalleled event dedicated to revolutionizing donor testing\, screening\, and cell source selection. This is your chance to be at the forefront of scalable allogeneic manufacturing and streamline both supply chain and process development. \nWhy Attend? \n\nDive Deep: Explore the latest global regulatory requirements and donor testing innovations.\nCutting-Edge Insights: Learn about breakthrough genome sequencing data transforming donor selection.\nForge Connections: Network with leading companies like Bristol Myers Squibb\, ImmuneBridge\, and Deverra Therapeutics.\nExclusive Access: Discover strategies to partner with donation sites and secure access to elite donor pools.\n\nBy refining our donor selection processes today\, we can revolutionize the future of allogeneic therapies and significantly enhance patient outcomes. \nLearn more here.
URL:http://www.pharmajournalist.com/event/2nd-donor-selection-cell-source-summit/
LOCATION:DoubleTree by Hilton Hotel San Diego – Mission Valley\, 7450 Hazard Center Dr\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241113
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T044530
CREATED:20240815T164748Z
LAST-MODIFIED:20240819T230624Z
UID:39587-1731456000-1731628799@www.pharmajournalist.com
SUMMARY:World Companion Diagnostics & Liquid Biopsy Summit APAC
DESCRIPTION:In the last 12 months\, precision healthcare in the Asia-Pacific region has seen a surge in technology advancements\, including NGS and laboratory developed tests\, approvals such as a companion diagnostic test for lung cancer\, and evolving regulations throughout the region. \nThe World Companion Diagnostics & Liquid Biopsy Summit APAC has been put together to provide a dedicated forum for key stakeholders from biopharma\, diagnostic providers and leading academics to overcome critical challenges in liquid biopsy and companion diagnostic (CDx) testing. \n\nWhere: Conrad Centennial\, Singapore\nWhen: November 13-14\, 2024\nWho: 100+ precision medicine experts from across the APAC region and wider globe\n\nDownload the event agenda here: https://ter.li/3qxsp8 \nThis unique and important forum is uniting experts from Singapore\, Australia\, China\, Japan\, Taiwan\, the USA and more to create a comprehensive framework for successful drug-companion diagnostic co-development and robust biomarker testing to accelerate patient access to personalized healthcare for improved outcomes in the APAC market. \nThis conference is FREE* to attend for drug developers and academics\, see the website for full terms and conditions here: https://ter.li/ewpxoe
URL:http://www.pharmajournalist.com/event/world-companion-diagnostics-liquid-biopsy-summit-apac/
LOCATION:Conrad Centennial\, 2 Temasek Blvd\, Singapore\, 038982\, Singapore
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241114
DTSTAMP:20260515T044530
CREATED:20240906T115503Z
LAST-MODIFIED:20240906T115503Z
UID:39712-1731369600-1731542399@www.pharmajournalist.com
SUMMARY:Advanced Therapies USA
DESCRIPTION:The Advanced Therapies Congress showcases the future of advanced therapies. Bringing Europe’s largest cell and gene therapy conference and exhibition to Philadelphia\, the event is for the leaders of the world’s ATMP developers and their most senior executives in charge of the latest tech and strategies that are driving the industry forward. This year\, we will be expecting 1000+ attendees\, 200 speakers\, 100+ sponsors and exhibitors\, join us now! \nTo know more visit: www.terrapinn.com/adtusa/pj/index 
URL:http://www.pharmajournalist.com/event/advanced-therapies-usa/
LOCATION:Pennsylvania Convention Center\, Philadelphia
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T044530
CREATED:20240815T164037Z
LAST-MODIFIED:20240815T164037Z
UID:39582-1731369600-1731628799@www.pharmajournalist.com
SUMMARY:8th Dermatology Drug Development Summit
DESCRIPTION:The advanced therapy immuno-inflammatory dermatology market is undergoing unprecedented expansion\, as Johnson & Johnson make a $3.35B play for bispecific candidates\, Alumis secured $259M series C and Galderma\, Incyte\, and Eli Lilly unveil late-breaking data. \nWith a fast-evolving drug development landscape\, remaining at the forefront of promising targets is now more crucial than ever. That’s why we’re delighted to announce the return of the 8th Dermatology Drug Development Summit (November 12-14 | Boston\, MA)\, the definitive industry-led forum uniting 130+ large pharma\, biotech\, and clinician KOLs to discover and develop best-in-class drugs for immuno-inflammatory skin disease. \nExplore the end-to-end conference program here: https://ter.li/5j7wx4 \nFeaturing 30+ expert speakers from the likes of Alys Pharmaceuticals\, LEO Pharma\, Incyte and AbbVie\, program highlights include: \n\n2 NEW tracks on Discovery & Translation to the Clinic and Clinical & Commercial Strategy\, providing more depth of content supporting disease pathogenesis understandings and novel target validation\, through demonstrating durable clinical efficacy whilst navigating nuanced market access challenges\n4 hands-on workshops pairing data-driven insights with collaborative problem-solving discussions to drive therapeutic progress in Hidradenitis Suppurativa\, JAK Inhibitors and Assets Targeting Multiple Indications\, plus laying foundations for Recruitment and Retention finesse.\n\nIncreased drug development landscape visibility\, including clinical case studies from early to late-stage programs\, all with dedicated Q&A time\, for Monoclonal Antibodies\, Oral and Topical Small Molecules\, Oral Peptides\, siRNA Lipid Conjugates\, Bispecific Antibodies and more! \nHere’s a snapshot of who you will meet: \nTakeda | MoonLake Immunotherapeutics | Seagen | Astria Therapeutics | Aditum Bio | Shaperon | Lynk Pharma | CAGE Bio | Sanofi | Edesa Biotech | Arcutis Biotherapeutics | AbbVie | GSK | Carocell Bio | Enveda Biosciences | Zura Bio | Incyte | UNION Therapeutics | Merck | Hudson Therapeutics | J&J | LEO Pharma | Recludix Pharma | Lynk Pharmaceuticals \nStay ahead of the scientific and commercial challenges in inflammatory disease drug development to set yourself up for success in 2025! \nQuick links: Website | Event Guide | Contact Us
URL:http://www.pharmajournalist.com/event/8th-dermatology-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR